Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
DURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today appointed Christopher L. Jordan as Vice President, Regulatory Affairs.
"We are pleased to announce the addition of Christopher Jordan to our leadership team as VP of Regulatory Affairs. Christopher brings over 30 years of pharmaceutical experience across various stages of product development. Some on our management team have had the pleasure of working with Christopher several years ago at Endocyte and Novartis where he recently led the regulatory strategy and execution of the FDA approval of Pluvicto and EMA submission of that agent. His vast knowledge in the oncology field will be a great addition to the team as we continue to development ONC201 and our other oncology pipeline products," said Mike Sherman, Chief Executive Officer of Chimerix.
"I am excited to be joining the Chimerix team as we advance a next generation of oncology therapies targeting areas of high unmet need. In particular, ONC201 has demonstrated rare single-agent activity in H3 K27M-mutant glioma which is a devasting disease with a poor prognosis. I am energized to work with FDA and other regulatory agencies to help bring this potential medicine to patients as quickly as possible," said Christopher Jordan, Vice President, Regulatory Affairs at Chimerix.
Mr. Jordan joins Chimerix from Novartis where he was most recently Senior Global Program Regulatory Director. Prior to that role he was Americas Head of Regulatory Affairs at Novartis's wholly-owned subsidiary, Advanced Accelerator Applications. Prior to Novartis, Mr. Jordan was the Vice President, Regulatory Affairs at Endocyte, Inc, an oncology-focused biotechnology company. Mr. Jordan began his career at Eli Lilly and Company in a range of product development and regulatory affairs roles. He also served as an adjunct professor of regulatory affairs at George Washington University from 2017 to 2019.
Mr. Jordan earned his Master of Science in Health Science in Regulatory Affairs from George Washington University, and Bachelor Science in Chemistry from Purdue University.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of such words as "will," "expects," "plans," "intends," "believes," and similar expressions that do not relate to historical matters. Forward-looking statements in this press release include, but are not limited to, statements, inferences, beliefs or expectations regarding: the Company's plans, objectives and intentions that are not historical facts generally. These statements reflect the current intent, beliefs and expectations of the Company's management. They involve known and unknown risks, uncertainties and other factors that may cause future events, including the Company's performance and results to differ materially from those expressed or implied by the forward-looking statements. Factors that may cause actual future events to differ from those in the forward-looking statements. See also the factors described under the heading "Item 1A -- Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, or as otherwise described in our other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
[email protected]
Will O'Connor
Stern Investor Relations
212-362-1200
[email protected]
